Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAP Adaptimmune Therapeutics PLC

Market Closed 04-17 16:00:00 EDT

0.2382

-0.0018

-0.75%

盘后0.2381

-0.0001-0.04%

18:11 EDT

High0.2461	Low0.2354	Vol302.09K
Open0.2461	D1 Closing0.2400	Amplitude4.46%
Mkt Cap61.27M	Tradable Cap41.80M	Total Shares257.23M
T/O72.64K	T/O Rate0.17%	Tradable Shares175.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ADAP","market":"US","secType":"STK","nameCN":"Adaptimmune Therapeutics PLC","latestPrice":0.2382,"timestamp":1744920000000,"preClose":0.24,"halted":0,"volume":302086,"hourTrading":{"tag":"盘后","latestPrice":0.2381,"preClose":0.2382,"latestTime":"18:11 EDT","volume":1211,"amount":289.32,"timestamp":1744927912772},"delay":0,"floatShares":175463180,"shares":257231941,"eps":-0.3,"marketStatus":"Market Closed","change":-0.0018,"latestTime":"04-17 16:00:00 EDT","open":0.2461,"high":0.2461,"low":0.2354,"amount":72635.94431939999,"amplitude":0.044583,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.3,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":1,"adrRate":6,"listingDate":1430884800000,"exchange":"NASDAQ","adjPreClose":0.24,"preHourTrading":{"tag":"盘前","latestPrice":0.257,"preClose":0.24,"latestTime":"09:26 EDT","volume":381,"amount":97.0371186,"timestamp":1744896393563},"postHourTrading":{"tag":"盘后","latestPrice":0.2381,"preClose":0.2382,"latestTime":"18:11 EDT","volume":1211,"amount":289.32,"timestamp":1744927912772},"volumeRatio":0.22583133856612003,"impliedVol":0.0826,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/ADAP","defaultTab":"news","newsList":[{"id":"2527146779","title":"Adaptimmune Therapeutics Plc - CFO Gavin Wood's Termination Date Extended to August 31, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527146779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527146779?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 04:14","pubTimestamp":1744661677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QS242:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2527194991","title":"European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2527194991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527194991?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 23:32","pubTimestamp":1744644777,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising late Monday morning, up 1.19% to 1,327.75 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and healthcare company Grifols , which climbed 6.1% and 4%. They were followed by networking and telecoms company Ericsson  and pharmaceutical giant Novo Nordisk , which added 3.2% and 2.5%, respectively.The decliners from continental Europe were led by medical device maker Edap  and hotel and accommodation search platform Trivago , which fell 6.3% and 3.3% respectively.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics  and biopharmaceutical firm Adaptimmune Therapeutics , which were rising 4.3% and 1.4% respectively.The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals  and Mereo BioPharma , which lost 5.1% and 3.9% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADAP","BK4107","NVO.AU","SLN","ERIC","TRVG","BK4588","BK4532","BK4568","BK4554","AFG","BK4599","BK4535","BK7104","BK4515","EDAP","GRFS","IE00BZ1G4Q59.USD","BK4020","BNTX","BK4585","BDRX","LU0154236417.USD","BK4591","BK4082","IE00BKVL7J92.USD","BK4548","BK4007","BK4551","BK4117","BK4505","MREO","LU1093756325.SGD","BK4139","BK4077","LU1093756168.USD"],"gpt_icon":1},{"id":"2526888649","title":"Adaptimmune downgraded to Hold from Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2526888649","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526888649?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 04:25","pubTimestamp":1744403113,"startTime":"0","endTime":"0","summary":"JonesResearch downgraded Adaptimmune (ADAP) to Hold from Buy without a price target The firm cites the company’s capital overhang remaining as an o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptimmune-downgraded-to-hold-from-buy-at-jonesresearch-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptimmune-downgraded-to-hold-from-buy-at-jonesresearch-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2526691974","title":"European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2526691974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526691974?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 23:05","pubTimestamp":1744383914,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Friday morning, rising 1.55% to 1,293.05 on the S&P Europe Select ADR Index. The index is up more than 5% for the week.From continental Europe, the gainers were led by biopharmaceutical companies Cellectis  and argenx , which advanced 14% and 5.6% respectively. They were followed by pharmaceutical company Novo Nordisk  and biopharmaceutical company Genfit , which increased 4.6% and 2.5% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and internet advertising firm Criteo , which fell 4.3% and 4% respectively. They were followed by furniture manufacturer Natuzzi , which dropped 3.5%.From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals  and Amarin , which climbed 8.3% and 6.4% respectively. They were followed by pharmaceutical company Silence Therapeutics  and biopharmaceutical company NuCana , which ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","LU1093756325.SGD","BK4532","AFG","IE00BKVL7J92.USD","NVO.AU","BK4585","BK4599","GNFT","LU0648005311.SGD","DAVA","NVO","LU0109394709.USD","NTZ","BK4095","AMRN","BK4142","CRTO","IE00BZ1G4Q59.USD","DBVT","BK4139","ARGX","BK4117","BK4588","TRIB","LU1093756168.USD","BK4007","CLLS","DAVA.AU","BK4134","LU0154236417.USD","LU0320765992.SGD","BDRX","BK7104","IE00BFMHRM44.USD","ADAP","BK4107","CUK","LU0889565916.HKD","NCNA","BK4009","SLN","LU0084288595.USD","BK4082"],"gpt_icon":1},{"id":"2525081250","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2525081250","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525081250?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 23:15","pubTimestamp":1744125340,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.91% to 1,261.50 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and biopharmaceutical company Cellectis , which advanced 20% and 9.5% respectively. They were followed by biopharmaceutical company Genfit  and Spanish lender Banco Santander , which climbed 7.8% and 5% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and oil and gas company Eni , which lost 6.3% and 1.3% respectively. They were followed by telecommunications operator Telefonica  and oil and gas company TotalEnergies , which were down 0.7% and 0.6% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics  and cruise line operator Carnival , which rose 9.5% and 7.1% respectively. They were followed by biopharmaceutical companies Verona","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADAP","TRIB","BK4521","BK1610","BK4107","LU0516423091.SGD","BK1231","BK4115","BK4201","CLLS","BK4588","BK4096","HSBC","SAN","AFG","LU2237443549.SGD","LU0128525689.USD","LU2129689514.USD","BK1601","BK1572","LU0540923850.HKD","HSHD.SI","EDAP","GNFT","LU0634319403.HKD","SAN.AU","BK4585","00005","BDRX","BK4207","DBVT","BK4561","LU0516422440.USD","AKTX","03143","LU0417516738.SGD","HSBA.UK","TEF","LU0164880469.USD","TTE","BK4551","CUK","VRNA","LU2129689431.USD","LU2237443622.USD","BK4505","E","MREO","BK4139","EAF"],"gpt_icon":0},{"id":"2524014307","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524014307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524014307?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:11","pubTimestamp":1743520287,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.From continental Europe,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVAX","IE00BMPRXN33.USD","BK4588","WPP.AU","BK4521","IE00BMPRXR70.SGD","EQNR","DBVT","BK4082","SAN","BK4201","AKTX","AFG","BK4007","EDAP","LU0320765992.SGD","TRIB","LU0889565916.HKD","GNFT","BK4207","BK7142","BK4139","BK4117","ASND","BCYC","BK4020","ADAP","NOK","WPP","AUTL","SAN.AU","BK4547","SLN","BK4009","LU0109394709.USD","BK4585","NCNA","BK4107"],"gpt_icon":0},{"id":"2524970911","title":"Adaptimmune Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970911","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970911?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:47","pubTimestamp":1743508020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 07:47 ET (11:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ADAP"],"gpt_icon":0},{"id":"2524195159","title":"Adaptimmune Therapeutics Plc : H.c. Wainwright Cuts Target Price to $3 From $3.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2524195159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524195159?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:09","pubTimestamp":1743502168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nAZN3N4EAY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522250119","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522250119","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522250119?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:09","pubTimestamp":1743174595,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.49% to 1,404.43 on the S&P Europe Select ADR Index, which is about 1.5% lower for the week.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Genfit , which advanced 49% and 5.2% respectively. They were followed by pharmaceutical company Sanofi , which rose 1.5%.The decliners from continental Europe were led by internet advertising firm Criteo , which fell 3.6%. It was followed by internet browser company Opera  and financial services company Banco Bilbao Vizcaya Argentaria , which were down 3.1% and 2.8% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana  and utilities provider National Grid , which increased 5.6% and 2.9% respectively. They were followed by telecommunications operator Vodafone Group  and biopharmaceutical company Adaptimmune Therapeutics , which were up 2% and 1.6% re","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBVT","CUK","IE00BFXG1179.USD","BBVA","BK4207","SNY","AFG","BK4505","NCNA","VOD","BK4139","BK4585","BK4142","IE00BFMHRM44.USD","BK4521","BK4009","BK4532","BK4007","BK4107","MREO","AMRN","BK4023","OPRA","BK4208","GNFT","ADAP","CRTO","BK4117","BK4132","BK4588","NGG","BCS"],"gpt_icon":0},{"id":"2522085309","title":"Barclays Remains a Sell on Adaptimmune Therapeutics (ADAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085309?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:35","pubTimestamp":1743082533,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Sell rating on Adaptimmune Therapeutics (ADAP – Research Report) on March 25 and set a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-adaptimmune-therapeutics-adap?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-adaptimmune-therapeutics-adap?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522802854","title":"Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802854?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:50","pubTimestamp":1742997000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:50 ET (13:50 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ADAP"],"gpt_icon":0},{"id":"2522482154","title":"Adaptimmune Therapeutics Plc : Guggenheim Cuts Target Price to $1.75 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522482154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522482154?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:20","pubTimestamp":1742984409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2522006169","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006169?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:08","pubTimestamp":1742915311,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Tuesday morning, up 0.73% to 1,435.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0098860793.USD","BK4551","LU2129689514.USD","BK4117","ADAP","BK4134","BNTX","SLN","LU2129689605.HKD","AFG","DBVT","LU0648005311.SGD","BK4207","LU2237443382.USD","LU0084288595.USD","BK4139","BK4535","BDRX","NTZ","MREO","BK4505","ING.AU","LU2237443549.SGD","AKTX","LU2237443895.HKD","NCNA","SHEL","BK4107","EDAP","TTE","LU2237443978.SGD","LU0300736062.USD","BK4585","EVAX","BK4201","DAVA","LU0889565916.HKD","LU1162221912.USD","LU2237443465.HKD","BK4007","LU0320765992.SGD","ASND","LU0300736492.USD","LU2236285917.USD","BK7505","LU2129689431.USD","ING","DAVA.AU","BK4548","BK7141"],"gpt_icon":0},{"id":"2522023527","title":"Adaptimmune Therapeutics (ADAP) Gets a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023527?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:56","pubTimestamp":1742900214,"startTime":"0","endTime":"0","summary":"Scotiabank analyst George Farmer maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $1.40...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAP","BK4141","BK4139","MMAT"],"gpt_icon":0},{"id":"2522072340","title":"ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2522072340","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522072340?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 17:26","pubTimestamp":1742894760,"startTime":"0","endTime":"0","summary":"After the market closed on 3/24/25, Adaptimmune  filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $ per diluted ordinary share versus our $ estimate. Relative to our model, the EPS miss was largely a function of non-recurring restructuring costs of $6.0 million and a $10.4 million impairment loss on leasehold improvement assets related to ADAP’s UK manufacturing facility.From a distribution standpoint, 20 Authorized Treatment Centers  are currently up and running and accepting referrals, with senior executives reiterating expectations to complete the rollout of the full network of 30 ATCs by end of 2025 . Moreover, manufacturing turnaround times have remained quicker than expected thus far, with ample s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adap-4q24-earnings-review-eps-092600329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAP"],"gpt_icon":0},{"id":"2522700076","title":"BRIEF-Adaptimmune Therapeutics PLC - Enters Amendment To Loan And Security Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700076?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:43","pubTimestamp":1742849018,"startTime":"0","endTime":"0","summary":"BRIEF-Adaptimmune Therapeutics PLC - Enters Amendment To Loan And Security Agreement - SEC FilingMarch 24  - Adaptimmune Therapeutics PLC ADAP.O:ADAPTIMMUNE THERAPEUTICS PLC - ENTERS AMENDMENT TO LOAN AND SECURITY AGREEMENT - SEC FILINGADAPTIMMUNE THERAPEUTICS PLC - TO MAKE $25 MILLION LOAN PREPAYMENT - SEC FILINGSource text: [ID:n0001558370-25-003542]Further company coverage: ADAP.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2522000487","title":"Adaptimmune Therapeutics Plc - to Make $25 Mln Loan Prepayment - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522000487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522000487?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:42","pubTimestamp":1742848946,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71D3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADAP"],"gpt_icon":0},{"id":"2521610401","title":"Adaptimmune Therapeutics Plc : Scotiabank Cuts Target Price to $1.4 From $3.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2521610401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521610401?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:48","pubTimestamp":1742554107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q40LQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADAP","BK4139"],"gpt_icon":0},{"id":"2521424188","title":"Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521424188","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521424188?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 15:01","pubTimestamp":1742540516,"startTime":"0","endTime":"0","summary":"Q4 2024 Product Revenue: $1.2 million from Tecelra sales.Authorized Treatment Centers : 20 ATCs established, representing 2/3 of the planned network.Patient Apheresis in Q1 2025: 10 patients apheresed with 3 more scheduled, totaling 13 anticipated.Expected Q1 2025 Invoicing: 6 to 8 patients, three to four times the prior quarter.Projected 2025 Sales: Approximately $25 million, aligning with analyst forecasts.Manufacturing Performance: 100% of products manufactured to specification with no failures; turnaround time under 30 days.Reimbursement Success: Over 70% of commercial and Medicare lives covered with no denials.Cost Savings: $75 million to $100 million reduction in forward cash flow demands through 2028 by pausing pre-clinical programs.Cash Savings from Restructuring: $300 million over the period announced previously.GuruFocus has detected 6 Warning Signs with ADAP.Adaptimmune Therapeutics PLC  has paused spending on pre-clinical programs targeting PRAME and CD70, which may impact ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-therapeutics-plc-adap-q4-070156398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAP"],"gpt_icon":0},{"id":"2521242901","title":"Adaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2521242901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521242901?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 14:57","pubTimestamp":1742540273,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Repor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-receives-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-adap-receives-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4139","ADAP","MFG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptimmune.com","stockEarnings":[{"period":"1week","weight":0.1079},{"period":"1month","weight":-0.4766},{"period":"3month","weight":-0.5892},{"period":"6month","weight":-0.7173},{"period":"1year","weight":-0.7587},{"period":"ytd","weight":-0.5578}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.24176},{"month":2,"riseRate":0.3,"avgChangeRate":0.006803},{"month":3,"riseRate":0.4,"avgChangeRate":-0.056152},{"month":4,"riseRate":0.7,"avgChangeRate":0.081938},{"month":5,"riseRate":0.333333,"avgChangeRate":0.165831},{"month":6,"riseRate":0.3,"avgChangeRate":-0.040994},{"month":7,"riseRate":0.4,"avgChangeRate":-0.012797},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021406},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036238},{"month":10,"riseRate":0.1,"avgChangeRate":-0.217057},{"month":11,"riseRate":0.4,"avgChangeRate":0.056022},{"month":12,"riseRate":0.4,"avgChangeRate":0.005688}],"exchange":"NASDAQ","name":"Adaptimmune Therapeutics PLC","nameEN":"Adaptimmune Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptimmune Therapeutics PLC(ADAP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptimmune Therapeutics PLC,ADAP,Adaptimmune Therapeutics PLC股票,Adaptimmune Therapeutics PLC股票老虎,Adaptimmune Therapeutics PLC股票老虎国际,Adaptimmune Therapeutics PLC行情,Adaptimmune Therapeutics PLC股票行情,Adaptimmune Therapeutics PLC股价,Adaptimmune Therapeutics PLC股市,Adaptimmune Therapeutics PLC股票价格,Adaptimmune Therapeutics PLC股票交易,Adaptimmune Therapeutics PLC股票购买,Adaptimmune Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptimmune Therapeutics PLC(ADAP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptimmune Therapeutics PLC(ADAP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}